Parion Sciences focuses on developing innovative therapies for respiratory diseases, leveraging its proprietary technologies to enhance drug delivery and efficacy. The company specializes in the use of its unique platform that enables the formulation of inhaled therapies, which are designed to improve the treatment of conditions such as cystic fibrosis and chronic obstructive pulmonary disease (COPD). By utilizing advanced drug delivery systems, Parion aims to optimize the pharmacokinetics and pharmacodynamics of its therapeutic candidates, ensuring that medications reach their intended targets effectively.

In addition to its inhalation technology, Parion Sciences is committed to advancing its research in mucosal drug delivery, which is crucial for treating diseases affecting mucosal surfaces. The company’s scientific approach includes the development of novel compounds that can enhance the absorption and retention of drugs in the respiratory tract. This focus on improving drug formulation and delivery mechanisms positions Parion as a leader in the field of respiratory therapeutics, with a pipeline of products that promise to address unmet medical needs in respiratory health.

United States

Parion Sciences is a development stage company dedicated to research, development, and commercialization of treatments to restore patient's innate mucosal surface defenses.  In the eye and in the lung, our layer of protective mucus plays an important role in keeping our bodies healthy. Sometimes though, either through genetics, aging or environmental stimulus, our innate mucosal defense system can become compromised. Parion's science driven technologies target respiratory and ocular diseases in which the patient's ability to protect their mucosal surfaces is compromised.

Parion Sciences

Company Details